

国内版国际版

Microsoft Bing

The Role of Imaging in Evaluating the Response After Neoadjuvant

ALLIMAGESVIDEOS

932,000 ResultsAny time

The Role of Imaging in Current Treatment Strategies for ...  
<https://pubmed.ncbi.nlm.nih.gov/32901458>  
The Role of Imaging in Current Treatment Strategies for **Pancreatic Adenocarcinoma**. In **pancreatic cancer**, imaging plays an essential role in surveillance, diagnosis, resectability evaluation, and treatment response evaluation. **Pancreatic cancer surveillance** in high-risk individuals has been attempted using **endoscopic ultrasound (EUS)** or magnetic resonance ...

Radiological evaluation of response to neoadjuvant ...  
<https://pubmed.ncbi.nlm.nih.gov/27692675>  
However, several studies have shown that the radiological evaluation of the **response after neoadjuvant therapy** is difficult for **pancreatic carcinoma**. This article reviews the scientific

Search Tool

Turn off Hover

Add the Give

**Imaging response evaluation after novel neoadjuvant ...**<https://link.springer.com/article/10.1007/s10353-019-0598-5>

May 17, 2019 Imaging evaluation after neoadjuvant therapy remains a diagnostic dilemma. To date, better understanding of the specific transformations of PDAC under neoadjuvant agents could not be transformed into validated imaging criteria for defining response and selecting surgical candidates.

Cited by: 3

Author: Eva Maria Gassner, Paulina Poskaite

Publish Year: 2019

**Search Tools**[Turn off Hover Translation \(关闭翻译\)](#)**Response evaluation following neoadjuvant treatment of ...**<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600566>

Feb 27, 2013 Although post-neoadjuvant treatment imaging implied a low response rate, a high rate of complete resections was achieved. This seems to confirm that, though radiology has made a significant progress in defining locally advanced PDAC, there is place for further improvement.

Cited by: 7

Author: Chiara Tosolini, Christoph W Michalski, J. ...

Publish Year: 2013

**Molecular targets for diagnostic and intraoperative ...**<https://pubmed.ncbi.nlm.nih.gov/33004930>

Neoadjuvant systemic treatment is increasingly being integrated in the standard treatment of pancreatic ductal adenocarcinoma (PDAC) patients to improve oncological outcomes. Current available imaging techniques remain unreliable in assessing response to therapies, as they cannot distinguish between (vital) tumor tissue and therapy induced fibrosis (TIF).

Author: F A Vuijk, L D A N de Muijnck, L C Fra. ... Publish Year: 2020

**Response assessment in pancreatic ductal adenocarcinoma ...**<https://pubmed.ncbi.nlm.nih.gov/29243123>

Advances in surgical techniques and introduction of novel combination chemotherapy and radiation therapy regimens have necessitated the need for biomarkers for assessment of treatment response. Conventional imaging methods such as RECIST have been used for response evaluation in clinical trials particularly in patients with metastatic PDAC.


Cited by: 13

Author: Vinil Balyan, Hamed Kordbacheh, Arush ...

Publish Year: 2018

**Radiological evaluation of response to neoadjuvant ...**<https://www.sciencedirect.com/science/article/pii/S2211568416302200>

Dec 01, 2016 In a retrospective series of 129 patients with "borderline" PC they showed that, on the one hand, a tumor morphological response at imaging was rare after neoadjuvant therapy, and on the other hand, that the usual RECIST criteria were not suitable to evaluate the response. In 2013, we performed a comparative analysis of preoperative CT scans of 80 patients with pancreatic head



63283\_Auto\_Edited-check.docx

Quotes Excluded  
Bibliography Excluded

11%

**Name of Journal:** *World Journal of Gastroenterology*

Manuscript NO: 63283

Manuscript Type: MINIREVIEWS

### Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma

Zhang Y *et al.* Response evaluation after NAT for PDAC

Yun Zhang, Zi-Xing Huang, Bin Song

## Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Despite the development of multimodality treatments including surgical resection, radiotherapy, and chemotherapy, the long-term prognosis of patients with PDAC remains poor. Recently, the introduction of neoadjuvant treatment (NAT) has made more patients amenable to surgery, increasing the possibility of R0 resection, treatment of occult micro-metastasis, and prolongation of overall

### Match Overview

1	Internet 41 words crawled on 25-Jul-2019 <a href="http://mefadoc.com">mefadoc.com</a>	1%
2	Internet 41 words crawled on 15-Feb-2020 <a href="http://www.ajronline.org">www.ajronline.org</a>	1%
3	Internet 33 words crawled on 25-Feb-2020 <a href="http://pubs.rsna.org">pubs.rsna.org</a>	1%
4	Crossref 32 words S.-J. Cui, T.-Y. Tang, X.-W. Zou, Q.-M. Su, L. Feng, X.-Y. Gong "Role of imaging biomarkers for prognostic prediction"	1%
5	Crossref 36 words Eric He, Hsueh-Hsiu, Zhengyong Jin "Radiomics in planimetric head and neck cancer: a state of art review", <i>Journal</i>	1%
6	Internet 29 words crawled on 11-Dec-2016 <a href="http://www.vignnet.com">www.vignnet.com</a>	1%
7	Internet 28 words crawled on 23-Oct-2020 <a href="http://kyronline.org">kyronline.org</a>	1%
8	Crossref 24 words Ying Liu, Minghao Wu, Yuwei Zhang, Yuhong Luo et al "Using Biomarkers to Predict and Evaluate the Effectiveness of ..."	1%
9	Crossref 26 words Christophe Cassanotte, Amadou Mouneir, Jean-Pierre Laloitacelle, Eric Terribonne et al, "Locally Advanced Pancreas	<1%
10	Crossref 19 words	<1%

国内版 国际版

Role of imaging in evaluating the response after neoadjuvant treatm



ALL IMAGES VIDEOS

132,000 Results

Any time ▾

### [Imaging response evaluation after novel neoadjuvant ...](#)

<https://link.springer.com/article/10.1007/s10353-019-0598-5> ▾

May 17, 2019 · Imaging evaluation after neoadjuvant therapy remains a diagnostic dilemma. To date, better understanding of the specific transformations of PDAC under neoadjuvant agents could not be transformed into validated imaging criteria for defining response and selecting surgical candidates.

Cited by: 3

Author: Eva-Maria Gassner, Paulina Poskaite

Publish Year: 2019

### [Perfusion CT to Assess Response to Neoadjuvant ...](#)

<https://pubs.rsna.org/doi/10.1148/radiol.2019182561>

Jul 09, 2019 · There has been growing evidence that size-based anatomic imaging for evaluation of response to therapy in PDA has poor correlation with histologic response. Katz et al demonstrated that radiographic downstaging was rare after neoadjuvant therapy and that RECIST response was not a reliable treatment end point in borderline-resectable PDA.

Cited by: 5

Author: Ahmed Hamdy, Yasutaka Ichikawa, Yuta...

Publish Year: 2019

### [Molecular targets for diagnostic and intraoperative ...](#)

<https://pubmed.ncbi.nlm.nih.gov/33004930>

Neoadjuvant systemic treatment is increasingly being integrated in the standard treatment of pancreatic ductal adenocarcinoma (PDAC) patients to improve oncological outcomes. Current available imaging techniques remain unreliable in assessing response to therapies, as they cannot distinguish between (vital) tumor tissue and therapy induced fibrosis (TIF).

Author: F A Vuijk, L D A N de Muynck, L C Fr... Publish Year: 2020

### [Response assessment in pancreatic ductal adenocarcinoma ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29243123>

Advances in surgical techniques and introduction of novel combination chemotherapy and radiation therapy regimens have necessitated the need for biomarkers for assessment of treatment response. Conventional imaging methods such as RECIST have been used for response evaluation in clinical trials particularly in patients with metastatic PDAC.

Cited by: 13

Author: Vinit Baliyan, Hamed Kordbacheh, Anush...

Publish Year: 2018